Platelet-activating factor (PAF), released during inflammatory responses, increases microvascular permeability to fluid and macromolecules. Previous studies in the hamster cheek pouch microcirculation have shown that PAF-induced increases in permeability can be diminished by pretreatment with a nitric oxide synthase inhibitor indicating that nitric oxide is required for PAF to cause leakage, although nitric oxide itself does not cause leakage. We evaluated the hypothesis that PAF stimulates the production of reactive oxygen species (ROS) that then react with nitric oxide to form a new species that signals the increase in vascular permeability. The hamster cheek pouch microcirculation was used to quantify the leakage of FITC-dextran following topical application of PAF. PAF-induced leakage was markedly inhibited (70%) by prior superfusion of the cheek pouch with superoxide dismutase and catalase. Superfusing the cheek pouch with ROS generated by xanthine oxidase and hypoxanthine produced leakage similar to that observed with PAF. Pretreating the cheek pouch with a nitric oxide synthase inhibitor (Nω-nitro-L-arginine, L-NA) inhibited ROS-induced leakage by 59% and PAF-induced leakage by 64%. The effects of L-NA and superoxide dismutase plus catalase on PAF-induced leakage were not additive. Systemic administration of mercaptoethylguanidine, a peroxynitrite scavenger, inhibited PAF-induced leakage by 60%. These results suggest that PAF-induced leakage may be mediated by an interaction between ROS and NO, perhaps through the formation of peroxynitrite or one of its products.

1.
Benveniste J: Platelet-activating factor (PAF-acether): Present status. Agents Actions 1981;11:542–544.
2.
Dillon PK, Fitzpatrick MF, Ritter AB, Duran WN: Effect of platelet activating factor on leukocyte adhesion to microvascular endothelium. Inflammation 1988;12:563–573.
3.
Kubes P, Suzuki M, Granger DN: Modulation of PAF-induced leukocyte adherence and increased microvascular permeability. Am J Physiol 1990;259:G859-G864.
4.
Dillon PK, Ritter AB, Duran WN: Vasoconstrictor effects on platelet-activating factor in the hamster cheek pouch microcirculation: Dose-related relations and pathways of action. Circ Res 1988;62:722–731.
5.
Kubes P, Suzuki M, Granger DN: Platelet-activating factor-induced microvascular dysfunction: Role of adherent leukocytes. Am J Physiol 1990;258:G158–G163.
6.
Bjork J, Smedegard G: Acute microvascular effects of PAF-acether, as studied by intravital microscopy. Eur J Pharmacol 1983;96:87–94.
7.
Schwappach JR, Wood JG, Cheung LY: Superoxide dismutase attenuates effects of platelet-activating factor on gastric microcirculation. J Surg Res 1995;59:733–738.
8.
Dillon PK, Duran WN: Effect of platelet-activating factor on microvascular permselectivity: Dose-response relations and pathways of action in the hamster cheek pouch microcirculation. Circ Res 1988;62:732–740.
9.
Harris NR, Granger DN: Mechanisms underlying enhanced capillary filtration induced by platelet-activating factor. Am J Physiol 1996;270:H127–H133.
10.
Bekker AY, Dillon PK, Paul J, Ritter AB, Duran WN: Dose-response relationships between platelet activating factor and permeability-surface area product of FITC-dextran 150 in the hamster cheek pouch. Microcirc Endothelium Lymphatics 1988;4:433–446.
11.
Kubes P, Arfors KE, Granger DN: Platelet-activating factor-induced mucosal dysfunction: Role of oxidants and granulocytes. Am J Physiol 1991;260:G965–G971.
12.
Kobayashi I, Kim D, Hobson RW, Duran WN: Platelet-activating factor modulates microvascular transport by stimulation of protein kinase C. Am J Physiol 1994;266:H1214–H1220.
13.
Ramirez MM, Kim DD, Duran WN: Protein kinase C modulates microvascular permeability through nitric oxide synthase. Am J Physiol 1996;271:H1702–H1705.
14.
Kim D, Duran WN: Platelet-activating factor stimulates protein tyrosine kinase in hamster cheek pouch microcirculation. Am J Physiol 1995;268:H399–H403.
15.
Oshiro H, Kobayashi I, Kim D, Takenaka H, Hobson RW, Duran WN: L-type calcium channel blockers modulate the microvascular hyperpermeability induced by platelet-activating factor in vivo. J Vasc Surg 1995;22:732–741.
16.
Ramirez MM, Quardt SM, Kim D, Oshiro H, Minnicozzi M, Duran WN: Platelet-activating factor modulates microvascular permeability through nitric oxide synthesis. Microvasc Res 1995;50:223–234.
17.
Klabunde RE, Anderson DE: Obligatory role of nitric oxide in platelet-activating factor-induced microvascular leakage. Eur J Pharmacol 2000;404:387–394.
18.
Jeon SY, Kim EA, Ma YW, Kim JP, Jung TG, Hwang EG: Nitric oxide mediates platelet activating factor-induced microvascular leakage in rat airways. Ann Otol Rhinol Laryngol 2001;110:83–86.
19.
Kurose I, Argenbright LW, Wolf R, Granger DN: Oxidative stress during platelet-activating factor-induced microvascular dysfunction. Microcirculation 1996;3:401–410.
20.
Szabo C, Ferrer-Sueta G, Zingarelli B, Southan GJ, Salzman AL, Radi R: Mercaptoethylguanidine and guanidine inhibitors of nitric-oxide synthase react with peroxynitrite and protect against peroxynitrite-induced oxidative damage. J Biol Chem 1997;272:9030–9036.
21.
Cuzzocrea S, Zingarelli B, Hake P, Salzman AL, Szabo C: Antiinflammatory effects of mercaptoethylguanidine, a combined inhibitor of nitric oxide synthase and peroxynitrite scavenger, in carrageenan-induced models of inflammation. Free Radic Biol Med 1998;24:450–459.
22.
Zingarelli B, Ischiropoulos H, Salzman AL, Szabo C: Amelioration by mercaptoethylguanidine of the vascular and energetic failure in haemorrhagic shock in the anesthetised rat. Eur J Pharmacol 1997;338:55–65.
23.
Schmidt J, Lindstaedt R, Szelenyi I: Characterization of platelet-activating factor induced superoxide anion generation by guinea-pig alveolar macrophages. J Lipid Mediat 1992;5:13–22.
24.
Matsuda T, Eccleston CA, Rubinstein I, Rennard SI, Joyner MJ: Antioxidants attenuate endotoxin-induced microvascular leakage of macromolecules in vivo. J Appl Physiol 1991;70:1483–1489.
25.
Granger DN: Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury. Am J Physiol 1988;255:H1269–H1275.
26.
Parks DA, Shah AK, Granger DN: Oxygen radicals: Effects on intestinal vascular permeability. Am J Physiol 1984;247:G167–G170.
27.
Del Maestro RF: Role of superoxide anion radicals in microvascular permeability and leukocyte behaviour. Can J Physiol Pharmacol 1982;60:1406–1414.
28.
Bjork J, Del Maestro RF, Arfors KE: Evidence for participation of hydroxyl radical in increased microvascular permeability. Agents Actions Suppl 1980;7:208–213.
29.
Yoshikawa T, Takano H, Yamamoto H, Nakahashi Y, Yamaguchi T, Arimoto T, et al: Role of superoxide and nitric oxide in platelet-activating factor-induced acute lung injury, hypotension, and mortality in rats. Crit Care Med 1997;25:286–292.
30.
Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and the ugly. Am J Physiol 1996;271:C1424–C1437.
31.
Wolin MS: Reactive oxygen species and vascular signal transduction mechanisms. Microcirculation 1996;3:1–17.
32.
Hogg N, Darley-Usmar VM, Wilson MT, Moncada S: Production of hydroxyl radicals from the simultaneous generation of superoxide and nitric oxide. Biochem J 1992;281:419–424.
33.
Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA: Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620–1624.
34.
Menconi MJ, Unno N, Smith M, Aguirre DE, Fink MP: Nitric oxide donor-induced hyperpermeability of cultured intestinal epithelial monolayers: Role of superoxide radical, hydroxyl radical, and peroxynitrite. Biochim Biophys Acta 1998;1425:189–203.
35.
Kennedy M, Denenberg AG, Szabo C, Salzman AL: Poly(ADP-ribose) synthetase activation mediates increased permeability induced by peroxynitrite in Caco-2BBe cells. Gastroenterology 1998;114:510–518.
36.
Imaizumi S, Kondo T, Deli MA, Gobbel G, Joo F, Epstein CJ, et al: The influence of oxygen free radicals on the permeability of the monolayer of cultured brain endothelial cells. Neurochem Int 1996;29:205–211.
37.
Abe J, Berk BC: Reactive oxygen species as mediators of signal transduction in cardiovascular disease. Trends Cardiovasc Med 1998;8:59–64.
38.
Qu XW, Rozenfeld RA, Huang W, Bulkley GB, Hsueh W: The role of xanthine oxidase in platelet activating factor induced intestinal injury in the rat. Gut 1999;44:203–211.
39.
Elliott SJ: Peroxynitrite modulates receptor-activated Ca2+ signaling in vascular endothelial cells. Am J Physiol 1996;270:L954–L961.
40.
Davidson CA, Kaminski PM, Wolin MS: NO elicits prolonged relaxation of bovine pulmonary arteries via endogenous peroxynitrite generation. Am J Physiol 1997;273:L437–L444.
41.
Huang YC, Nozik ES, Piantadosi CA: Superoxide dismutase potentiates platelet-activating factor-induced injury in perfused lung. Am J Physiol 1994;266:L246–L254.
42.
Southan GJ, Zingarelli B, O’Connor M, Salzman AL, Szabo C: Spontaneous rearrangement of aminoalkylisothioureas into mercaptoalkylguanidines, a novel class of nitric oxide synthase inhibitors with selectivity towards the inducible isoform. Br J Pharmacol 1996;117:619–632.
43.
Zingarelli B, Southan GJ, Gilad E, O’Connor M, Salzman AL, Szabo C: The inhibitory effects of mercaptoalkylguanidines on cyclo-oxygenase activity. Br J Pharmacol 1997;120:357–366.
44.
Filep JG, Foldes-Filep E: Modulation by nitric oxide of platelet-activating factor-induced albumin extravasation on the conscious rat. Br J Pharmacol 1993;110:1347–1352.
45.
Fujii E, Irie K, Uchida Y, Ohba K, Muraki T: Role of eicosanoids but not nitric oxide in the platelet-activating factor-induced increase in vascular permeability in mouse skin. Eur J Pharmacol 1995;273:267–272.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.